Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis
- PMID: 28476876
- PMCID: PMC5524067
- DOI: 10.1161/JAHA.116.004896
Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis
Abstract
Background: The aim of the present study was to estimate the impact of dehydroepiandrosterone sulfate (DHEAS) on the prognosis of patients with cardiovascular disease by performing a systematic review and meta-analysis.
Methods and results: The Embase, PubMed, Web of Science, CNKI, and WanFang databases were searched up to September 5, 2016, to identify eligible studies. The quality of each study was assessed using the Newcastle-Ottawa Scale. The association between DHEAS, either on admission or at discharge, and cardiovascular disease outcomes were reviewed. The overall risk ratio for the effect of DHEAS on all-cause mortality and fatal and nonfatal cardiovascular events was pooled using a fixed-effects or a random-effects model. The publication bias was evaluated using funnel plots. Twenty-five studies were included for systematic review. The follow-up duration ranged from 1 to 19 years. Eighteen studies were included in the meta-analysis. We found that lower DHEAS levels indicated a significant increased risk for all-cause mortality (risk ratio, 1.47; 95% CI, 1.38-1.56 [P<0.00001]), fatal cardiovascular event (risk ratio, 1.58; 95% CI, 1.30-1.91 [P<0.00001]), and nonfatal cardiovascular event (risk ratio, 1.42; 95% CI, 1.24-1.62 [P<0.0001]) in patients with cardiovascular disease.
Conclusions: Patients with cardiovascular disease who have lower DHEAS levels may have poorer prognosis than those with higher DHEAS levels.
Keywords: cardiovascular disease; dehydroepiandrosterone sulfate; meta‐analysis; prognosis; sex hormones; systematic review.
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Figures
Similar articles
-
Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies.Acta Cardiol. 2003 Oct;58(5):403-10. doi: 10.2143/AC.58.5.2005304. Acta Cardiol. 2003. PMID: 14609305 Review.
-
Circulating dehydroepiandrosterone sulfate level and cardiovascular or all-cause mortality in the elderly population: a meta-analysis.Ann Palliat Med. 2020 Sep;9(5):3537-3545. doi: 10.21037/apm-20-441. Epub 2020 Sep 7. Ann Palliat Med. 2020. PMID: 32921089
-
Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population.Aging (Milano). 1999 Feb;11(1):30-4. Aging (Milano). 1999. PMID: 10337439
-
Trajectories of dehydroepiandrosterone sulfate predict mortality in older adults: the cardiovascular health study.J Gerontol A Biol Sci Med Sci. 2009 Dec;64(12):1268-74. doi: 10.1093/gerona/glp129. Epub 2009 Aug 27. J Gerontol A Biol Sci Med Sci. 2009. PMID: 19713299 Free PMC article.
-
Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease.J Endocrinol. 1996 Sep;150 Suppl:S149-53. J Endocrinol. 1996. PMID: 8943798 Review.
Cited by
-
Dehydroepiandrosterone Sulfate, an Adrenal Androgen, Is Inversely Associated with Prevalence of Dynapenia in Male Individuals with Type 2 Diabetes.Metabolites. 2023 Nov 3;13(11):1129. doi: 10.3390/metabo13111129. Metabolites. 2023. PMID: 37999225 Free PMC article.
-
Improving the prognostic value of multimorbidity through the integration of selected biomarkers to the comprehensive geriatric assessment: An observational retrospective monocentric study.Front Med (Lausanne). 2022 Oct 31;9:999767. doi: 10.3389/fmed.2022.999767. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36388885 Free PMC article.
-
Testosterone Deficiency and Nutritional Parameters as Predictors of All-Cause Mortality among Male Dialysis Patients.Nutrients. 2022 Oct 24;14(21):4461. doi: 10.3390/nu14214461. Nutrients. 2022. PMID: 36364724 Free PMC article.
-
Early Changes in Androgen Levels in Individuals with Spinal Cord Injury: A Longitudinal SwiSCI Study.J Clin Med. 2022 Nov 4;11(21):6559. doi: 10.3390/jcm11216559. J Clin Med. 2022. PMID: 36362788 Free PMC article.
-
Dehydroepiandrosterone inhibits vascular proliferation and inflammation by modulating the miR-486a-3p/NLRP3 axis.Am J Transl Res. 2022 Sep 15;14(9):6123-6136. eCollection 2022. Am J Transl Res. 2022. PMID: 36247250 Free PMC article.
References
-
- Regelson W, Kalimi M. Dehydroepiandrosterone (DHEA)—the multifunctional steroid. II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action? Ann N Y Acad Sci. 1994;719:564–575. - PubMed
-
- Labrie F. Intracrinology. Mol Cell Endocrinol. 1991;78:C113–C118. - PubMed
-
- Zwain IH, Yen SS. Dehydroepiandrosterone: biosynthesis and metabolism in the brain. Endocrinology. 1999;140:880–887. - PubMed
-
- Cox JL, Chang Y, Ramaraj P. In‐vitro determination of biological and anabolic functions of weak androgen dehydroepiandrosterone (DHEA) using a variety of cell lines. Open J Endocr Metab Dis. 2015;5:105–116.
-
- Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res. 2010;182:97–148. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources